To date, there are 9 FDA approvals for the use of ICB based on a specific PD-L1 threshold and companion diagnostic, with variable thresholds both within and across tumor types using several different assays, including approvals at the following PD-L1 positive percentage thresholds: 1, 5, and 50%. Here, CD274 is linked to neoplasm.